Scanwell Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Scanwell Health is a digital diagnostics company that enables consumers to perform lab-quality rapid tests at home and receive clinician-reviewed digital results through a smartphone app. HQ: Los Angeles.
About
Scanwell Health is a digital diagnostics company that combines FDA-cleared rapid diagnostic tests with a smartphone scanning platform and telemedicine services to deliver lab-quality health testing and clinical interpretation at home. Users purchase a Scanwell test kit, perform the rapid test (using a blood, urine, or swab sample depending on the test type), photograph the test strip with their smartphone camera, and receive an AI-analyzed result with optional clinician review and prescription if needed. The platform creates a complete at-home testing and care pathway for conditions ranging from UTIs to COVID-19 to sexually transmitted infections.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.